A Study of DS-7011a in Patients With Systemic Lupus Erythematosus
| Condition | Systemic Lupus Erythematosus |
|---|---|
| Phase | Phase 1/2 |
| Sponsor | Daiichi Sankyo |
| Status | Completed |
| Enrollment | 26 participants |
| Interventions | DS-7011a |
| Start date | Jun 7, 2023 |
| Completion date | Apr 1, 2025 |
| Results posted | May 28, 2026 |
Summary
Systemic lupus erythematosus (SLE) is a systemic chronic autoimmune disease characterized by autoantibody production, inflammation, and tissue damage in multiple organs. Standard of care therapies used to treat SLE are only partially effective and have a wide range of toxicities. There is a need for more effective and safer therapies for patients with SLE.
Number of Participants With Treatment-emergent Adverse Events Following Administration With DS-7011a in Participants With Systemic Lupus Erythematosus
| DS-7011a | 11 Participants |
|---|---|
| Placebo | 4 Participants |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacok — Viatris Innovation GmbH
- Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With — Viatris Innovation GmbH
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2 — Hoffmann-La Roche
- Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults — Duke University
- Reducing Disparities in Medication Adherence in SLE — Duke University
- Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pa — Northwell Health